Abstract: Angiogenesis plays an important role in tumor growth and metastasis, and vascular endothelial growth factor receptor 2 (VEGFR2) is a key regulatory factor in the process of angiogenesis. Apatinib mesylate is a small molecule tyrosine kinase inhibitor developed over ten years in China. At present, apatinib as single agent has been successfully used in the clinical treatment of advanced gastric cancer, non-small cell lung cancer and breast cancer, etc. The combination of apatinib and other anti-tumor therapies often increases the efficacy and reduces side effects at the same time. In this review, the therapeutic effect and mechanism of apatinib combined with other therapies for varies of tumors were briefly summarized, according to recently reported clinical cases and preclinical researches.